Literature DB >> 26065566

Treatment outcomes of obstructive sleep apnoea in obese community-dwelling children: the NANOS study.

María Luz Alonso-Álvarez1, Joaquin Terán-Santos2, Ana Isabel Navazo-Egüia3, Mónica Gonzalez Martinez4, María José Jurado-Luque5, Jaime Corral-Peñafiel6, Joaquin Duran-Cantolla7, José Aurelio Cordero-Guevara3, Leila Kheirandish-Gozal8, David Gozal8.   

Abstract

The first line of treatment of obstructive sleep apnoea syndrome (OSAS) in children consists of adenotonsillectomy (T&A). The aim of the present study was to evaluate treatment outcomes of OSAS among obese children recruited from the community.A cross-sectional, prospective, multicentre study of Spanish obese children aged 3-14 years, with four groups available for follow-up: group 1: non-OSAS with no treatment; group 2: dietary treatment; group 3: surgical treatment; and group 4: continuous positive airway pressure treatment.117 obese children (60 boys, 57 girls) with a mean age of 11.3±2.9 years completed the initial (T0) and follow-up (T1) assessments. Their mean body mass index (BMI) at T1 was 27.6±4.7 kg·m(-2), corresponding to a BMI Z-score of 1.34±0.59. Mean respiratory disturbance index (RDI) at follow-up was 3.3±3.9 events·h(-1). Among group 1 children, 21.2% had an RDI ≥3 events·h(-1) at T1, the latter being present in 50% of group 2, and 43.5% in group 3. In the binary logistic regression model, age emerged as a significant risk factor for residual OSAS (odds ratio 1.49, 95% confidence interval 1.01-2.23; p<0.05) in obese children surgically treated, and RDI at T0 as well as an increase in BMI emerged as significant risk factors for persistent OSAS in obese children with dietary treatment (OR 1.82, 95% CI 1.09-3.02 (p<0.03) and OR 8.71, 95% CI 1.24-61.17 (p=0.03)).Age, RDI at diagnosis and obesity are risk factors for relatively unfavourable OSAS treatment outcomes at follow-up.
Copyright ©ERS 2015.

Entities:  

Mesh:

Year:  2015        PMID: 26065566     DOI: 10.1183/09031936.00013815

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

1.  Potential Anatomic Markers of Obstructive Sleep Apnea in Prepubertal Children.

Authors:  Chun Ting Au; Kate Ching Ching Chan; Kin Hung Liu; Winnie Chiu Wing Chu; Yun Kwok Wing; Albert Martin Li
Journal:  J Clin Sleep Med       Date:  2018-12-15       Impact factor: 4.062

2.  Montelukast for Children with Obstructive Sleep Apnea: Results of a Double-Blind, Randomized, Placebo-Controlled Trial.

Authors:  Leila Kheirandish-Gozal; Hari P R Bandla; David Gozal
Journal:  Ann Am Thorac Soc       Date:  2016-10

3.  Ambulatory clinical parameters and sleep respiratory events in a group of obese children unselected for respiratory problems.

Authors:  Marco Zaffanello; Giorgio Piacentini; Angelo Pietrobelli; Cristiano Fava; Giuseppe Lippi; Claudio Maffeis; Emma Gasperi; Luana Nosetti; Sara Bonafini; Angela Tagetti; Franco Antoniazzi
Journal:  World J Pediatr       Date:  2017-07-12       Impact factor: 2.764

4.  Pediatric Obstructive Sleep Apnea: What's in a Name?

Authors:  Allan Damian; David Gozal
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

5.  Progression of Obstructive Sleep Apnea Syndrome in Pediatric Patients with Prader-Willi Syndrome.

Authors:  Shi-Bing Wong; Mei-Chen Yang; I-Shiang Tzeng; Wen-Hsin Tsai; Chou-Chin Lan; Li-Ping Tsai
Journal:  Children (Basel)       Date:  2022-06-17

6.  IL-17A expression in the adenoid tissue from children with sleep disordered breathing and its association with pneumococcal carriage.

Authors:  Chien-Chia Huang; Pei-Wen Wu; Chyi-Liang Chen; Chun-Hua Wang; Ta-Jen Lee; Chi-Neu Tsai; Cheng-Hsun Chiu
Journal:  Sci Rep       Date:  2018-11-13       Impact factor: 4.379

7.  Improvement in BMI z-score following adenotonsillectomy in adolescents aged 12-18 years: a retrospective cohort study.

Authors:  Keren Nathan; Galit Livnat; Liat Feraru; Giora Pillar
Journal:  BMC Pediatr       Date:  2021-04-20       Impact factor: 2.125

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.